PMID- 36211958
OWN - NLM
STAT- MEDLINE
DCOM- 20221011
LR  - 20221012
IS  - 2235-2988 (Electronic)
IS  - 2235-2988 (Linking)
VI  - 12
DP  - 2022
TI  - Meglumine antimoniate was associated with a higher cure rate than liposomal 
      amphotericin B in the treatment of American tegumentary leishmaniasis: A 
      retrospective cohort study from a Leishmania braziliensis-endemic area.
PG  - 993338
LID - 10.3389/fcimb.2022.993338 [doi]
LID - 993338
AB  - BACKGROUND: Pentavalent antimonials (PAs) are the primary therapeutic option for 
      American tegumentary leishmaniasis (ATL). However, the use of these drugs is 
      complicated by adverse events (AEs), resistance and contraindications. 
      Alternative therapies relative effectiveness is not well established. OBJECTIVE: 
      This study compared the effectiveness of liposomal amphotericin B (LAB) with 
      intravenous meglumine antimoniate (NMG) in the treatment of ATL. We also analysed 
      and compared associated AEs and treatment interruption rates. METHODS: This was a 
      retrospective cohort study from Brazil. The potential risk factors for the 
      primary outcome were age, sex, total cutaneous lesion area, presence of mucosal 
      lesions, AEs and treatment interruption. The primary outcome was lesion healing 
      within 6 months of treatment. AEs and treatment interruption were also analysed. 
      Multiple analytic strategies were employed to evaluate the reliability of the 
      results. RESULTS: Before propensity score (PS) matching, patients in the LAB 
      group were older and had a higher frequency of mucosal lesions. The NMG group had 
      a higher cure rate than the LAB group (cure rate 88% versus 55% respectively) in 
      the adjusted analysis (relative risk (RR)=1.55 95% CI: 1.19 - 2.02) and after PS 
      matching (RR=1.63 95% CI: 1.20 - 2.21). NMG group had a higher AE rate (event 
      rate 52% versus 44%) in the adjusted analysis (RR= 1.61, 95% CI: 1.06 - 2.43, 
      p=0.02), but this result was not observed after PS matching (RR= 0.87, 95% CI: 
      0.49 -1.52, p= 0.61). CONCLUSIONS: We observed that the NMG group had a higher 
      cure rate than the LAB group, with an equivocally higher EV rate in the adjusted 
      analysis.
CI  - Copyright (c) 2022 Barroso, Goncalves, Barbosa, da Motta, Freire, Gomes and 
      Sampaio.
FAU - Barroso, Daniel Holanda
AU  - Barroso DH
AD  - Hospital Universitario de Brasilia, Universidade de Brasilia, Brasilia, Brazil.
AD  - Laboratorio de Dermatomicologia da Faculdade de Medicina, Universidade de 
      Brasilia, Brasilia, Brazil.
FAU - Goncalves, Renata Trindade
AU  - Goncalves RT
AD  - Hospital Universitario de Brasilia, Universidade de Brasilia, Brasilia, Brazil.
FAU - Barbosa, Joadyson Silva
AU  - Barbosa JS
AD  - Hospital Universitario de Brasilia, Universidade de Brasilia, Brasilia, Brazil.
FAU - da Motta, Jorgeth de Oliveira Carneiro
AU  - da Motta JOC
AD  - Hospital Universitario de Brasilia, Universidade de Brasilia, Brasilia, Brazil.
FAU - Freire, Gustavo Subtil Magalhaes
AU  - Freire GSM
AD  - Hospital Universitario de Brasilia, Universidade de Brasilia, Brasilia, Brazil.
FAU - Gomes, Ciro Martins
AU  - Gomes CM
AD  - Hospital Universitario de Brasilia, Universidade de Brasilia, Brasilia, Brazil.
AD  - Laboratorio de Dermatomicologia da Faculdade de Medicina, Universidade de 
      Brasilia, Brasilia, Brazil.
AD  - Programa de Pos-Graduacao em Ciencias Medicas, Faculdade de Medicina, 
      Universidade de Brasilia, Brasilia, Brazil.
FAU - Sampaio, Raimunda Nonata Ribeiro
AU  - Sampaio RNR
AD  - Hospital Universitario de Brasilia, Universidade de Brasilia, Brasilia, Brazil.
AD  - Laboratorio de Dermatomicologia da Faculdade de Medicina, Universidade de 
      Brasilia, Brasilia, Brazil.
AD  - Programa de Pos-Graduacao em Ciencias Medicas, Faculdade de Medicina, 
      Universidade de Brasilia, Brasilia, Brazil.
AD  - Pos-Graduacao de Ciencias da Saude da Faculdade de Ciencias Saude, Universidade 
      de Brasilia, Brasilia, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20220923
PL  - Switzerland
TA  - Front Cell Infect Microbiol
JT  - Frontiers in cellular and infection microbiology
JID - 101585359
RN  - 0 (Antiprotozoal Agents)
RN  - 0 (liposomal amphotericin B)
RN  - 75G4TW236W (Meglumine Antimoniate)
RN  - 7XU7A7DROE (Amphotericin B)
SB  - IM
MH  - Amphotericin B
MH  - *Antiprotozoal Agents/therapeutic use
MH  - Humans
MH  - *Leishmania braziliensis
MH  - *Leishmaniasis, Cutaneous/drug therapy
MH  - Meglumine Antimoniate/adverse effects/therapeutic use
MH  - Reproducibility of Results
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC9538529
OTO - NOTNLM
OT  - American cutaneous leishmaniasis (ACL)
OT  - N-methyl glucamine antimoniate
OT  - adverse effect
OT  - liposomal amphotericin B (LAB)
OT  - mucosal leishmaniasis
OT  - therapy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/11 06:00
MHDA- 2022/10/12 06:00
PMCR- 2022/01/01
CRDT- 2022/10/10 04:03
PHST- 2022/07/13 00:00 [received]
PHST- 2022/09/02 00:00 [accepted]
PHST- 2022/10/10 04:03 [entrez]
PHST- 2022/10/11 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fcimb.2022.993338 [doi]
PST - epublish
SO  - Front Cell Infect Microbiol. 2022 Sep 23;12:993338. doi: 
      10.3389/fcimb.2022.993338. eCollection 2022.